Browse by Phase
Phase 1 Clinical Trials
Phase 1 trials test a new drug or treatment in a small group (20–80 people) for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects.
Total Trials
589
Recruiting Now
589
Top Conditions in Phase 1
Frequently Asked Questions — Phase 1 Trials
What is tested in a Phase 1 clinical trial?
Phase 1 trials test a new drug or treatment in a small group of 20–80 people for the first time. The primary goals are to evaluate safety, determine a safe dosage range, identify side effects, and study how the drug is metabolized and excreted. Phase 1 trials typically enroll patients with the target condition who have exhausted standard treatment options, or healthy volunteers in some cases.
How long do Phase 1 clinical trials last?
Phase 1 trials typically last several months to one year depending on the drug, dose-escalation protocol, and follow-up period. The relatively small patient cohort and focused safety objectives make Phase 1 the shortest stage in clinical development. Some are extended into Phase 1/2 combined designs to simultaneously gather early efficacy signals.
Are Phase 1 clinical trials safe to join?
Phase 1 trials are the first human tests of a new intervention and carry the most uncertainty about safety. All Phase 1 studies must be approved by an Institutional Review Board (IRB) and operate under strict FDA oversight. Participants receive intensive monitoring throughout the study. While risks exist, Phase 1 protocols use conservative dosing and frequent safety assessments to protect participants.
Active Phase 1 Studies
NCT07483827 Phase 1
Recruiting
A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CP...
Condition
C3 Glomerulopathy (C3G)
Enrollment
39 pts
Location
Austria, Belgium, Czechia
Sponsor
eleva GmbH
NCT07672483 Phase 1
Recruiting
IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refrac...
Condition
Relapsed Solid Tumor Malignancies
Enrollment
95 pts
Location
United States
Sponsor
National Cancer Institute (NCI
NCT02811510 Phase 1
Recruiting
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol ...
Condition
Cannabis
Enrollment
40 pts
Location
United States
Sponsor
Yale University
NCT06413953 Phase 1
Recruiting
A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors
Condition
Advanced Cancers
Enrollment
140 pts
Location
China
Sponsor
Chia Tai Tianqing Pharmaceutic
NCT05866471 Phase 1
Recruiting
The ENHANCE Study: taVNS and Psilocybin
Condition
Healthy
Enrollment
115 pts
Location
United States
Sponsor
University of Wisconsin, Madis
NCT03860233 Phase 1
Recruiting
Benefits of Oxytocin in Obstructive Sleep Apnea (OSA) Patients Using Continuous ...
Condition
Sleep Apnea
Enrollment
40 pts
Location
United States
Sponsor
Vivek Jain
NCT06363006 Phase 1
Recruiting
Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced H...
Condition
Hepatocellular Carcinoma
Enrollment
40 pts
Location
China
Sponsor
Peking Union Medical College H
NCT06683066 Phase 1
Recruiting
Study on Human Bioequivalence of Triprerelin Acetate for Injection
Condition
Prostate Cancer (CRPC)
Enrollment
120 pts
Location
China
Sponsor
The Affiliated Hospital of Qin
NCT07500181 Phase 1
Recruiting
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BA...
Condition
Healthy
Enrollment
136 pts
Location
Netherlands
Sponsor
Basilea Pharmaceutica
NCT05762419 Phase 1
Recruiting
FUS Etoposide for DMG
Condition
Diffuse Intrinsic Pontine Glioma
Enrollment
10 pts
Location
United States
Sponsor
Columbia University
NCT06740799 Phase 1
Recruiting
Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impair...
Condition
Hepatic Impairment
Enrollment
12 pts
Location
United States
Sponsor
Daiichi Sankyo
NCT07888114 Phase 1
Recruiting
Preliminary Clinical Study of Entinostat in Children With Malignant Soft Tissue ...
Condition
Soft Tissue Sarcoma
Enrollment
16 pts
Location
China
Sponsor
Beijing Tongren Hospital
NCT05471856 Phase 1
Recruiting
A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlima...
Condition
Solid Tumors
Enrollment
66 pts
Location
United States, Japan, South Korea
Sponsor
Boehringer Ingelheim
NCT05369065 Phase 1
Recruiting
Ablation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comor...
Condition
Diabetes Mellitus, Type 2
Enrollment
60 pts
Location
Georgia
Sponsor
Neurotronic, Inc.
NCT07844694 Phase 1
Recruiting
Low-Dose Sirolimus for the Treatment of RUNX1 Familial Platelet Disorder
Condition
Familial Platelet Disorder With Associated Myeloid Malignancy
Enrollment
6 pts
Location
United States
Sponsor
OHSU Knight Cancer Institute
NCT07197645 Phase 1
Recruiting
Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain
Condition
Bone Pain
Enrollment
33 pts
Location
United States
Sponsor
Telix Pharmaceuticals (Innovat
NCT07309900 Phase 1
Recruiting
IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies
Condition
Relapsed/Refractory B-cell Malignancies
Enrollment
12 pts
Location
China
Sponsor
Union Hospital, Tongji Medical
NCT07584434 Phase 1
Recruiting
A Phase 1, First-in-human Study of VX-433
Condition
Narcolepsy Type 1 (NT1)
Enrollment
118 pts
Location
United States
Sponsor
Vertex Pharmaceuticals Incorpo
NCT07465965 Phase 1
Recruiting
A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults
Condition
Overweight
Enrollment
60 pts
Location
United States
Sponsor
Shanghai World Leader Pharmace
NCT07065409 Phase 1
Recruiting
Treatment of Moyamoya Disease With iPSC-derived Exosomes
Condition
Moyamoya Disease
Enrollment
9 pts
Location
China
Sponsor
Huaqiu Zhang
NCT06138132 Phase 1
Recruiting
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjec...
Condition
Multiple Sclerosis
Enrollment
12 pts
Location
United States
Sponsor
Stanford University
NCT07779798 Phase 1
Recruiting
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, a...
Condition
Advanced Solid Tumors
Enrollment
120 pts
Location
United States
Sponsor
Crossbow Therapeutics, Inc.
NCT07079930 Phase 1
Recruiting
Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healt...
Condition
Healthy Volunteers
Enrollment
10 pts
Location
Israel
Sponsor
Hadassah Medical Organization
NCT07014930 Phase 1
Recruiting
Identification of New Tools for Predicting Natural Metabolic Performance of the ...
Condition
Healthy Volunteers
Enrollment
40 pts
Location
Switzerland
Sponsor
Caroline Samer
NCT07240636 Phase 1
Recruiting
Study of Food Effects of VV119 Capsules in Chinese Healthy Volunteers
Condition
Healthy Volunteers
Enrollment
16 pts
Location
China
Sponsor
Vigonvita Life Sciences
Page 1 of 24 — 589 trials total
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology